Citicoline vs Alpha-GPC
Affiliate Disclosure: Some links on this page are affiliate links. If you purchase through them, NeuroEdge Formula earns a small commission at no extra cost to you. Peter only recommends products he has personally tested and that meet the evidence standards of this site.
Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Citicoline and Alpha-GPC interact with cholinergic neurotransmission and may not be appropriate for everyone. Consult a qualified healthcare provider before beginning supplementation, particularly if you have cardiovascular risk factors, take anticholinergic medications, or have a pre-existing neurological condition. Peter Benson is a cognitive enhancement researcher, not a medical doctor.
| The key distinction | These are not two versions of the same compound. Alpha-GPC is the superior acute cholinergic enhancer — faster, stronger, more bioavailable choline delivery. Citicoline is the broader neuroprotective agent — slower, more structural, with a phosphatidylcholine synthesis pathway that supports membrane repair alongside acetylcholine production. |
| Alpha-GPC best for | Acute cognitive performance — working memory, word retrieval, motivation quality. Faster onset than citicoline. 40% choline content by weight vs citicoline’s 18%. The preferred cholinergic for the performance-focused user. |
| Citicoline best for | Cognitive resilience and neuroprotection — slower, more sustained cognitive improvement, membrane repair benefit, dopaminergic effects via the cytidine pathway, with a better cardiovascular safety profile than Alpha-GPC. |
| Safety distinction | Alpha-GPC has an emerging TMAO cardiovascular risk signal — elevated plasma TMAO associated with cardiovascular risk in observational data. Not a definitive contraindication, but a consideration for those with cardiovascular risk factors. Citicoline does not share this pathway. |
| Standard doses | Alpha-GPC: 300–600mg daily. Citicoline: 250–500mg daily. Both taken in the morning with or without food. Can be combined at lower doses — this is not redundant, as the pathways differ. |
| Peter’s current use | Alpha-GPC 300mg for acute performance sessions. Citicoline 250mg (via Mind Lab Pro) for the structural neuroprotective layer daily. The combination addresses both the performance and the long-term brain health objectives simultaneously. |
| Biggest mistake | Treating the choice as binary. These compounds serve different purposes through different mechanisms. “Which one?” is often less useful than “which one for which goal?” — or whether a combination at moderate doses is the more complete answer. |
Here is the question I receive more consistently than almost any other in the choline category: citicoline or Alpha-GPC — which one should I take? The answer I give surprises most people. I tell them the question is usually wrong — not because both are equivalent, but because they operate through genuinely different pathways, serve different cognitive purposes, and carry different safety considerations. Comparing them as if you are choosing between two brands of the same product misses what makes each valuable, and leads to protocol decisions that underserve both goals.
I spent the better part of four years running systematic personal trials on both before I was confident enough to write about the distinction in a way I was satisfied with. My early experience with choline supplementation started with standard choline bitartrate, which did essentially nothing useful beyond producing a fishy body odour at higher doses. Alpha-GPC came next, and the difference was immediate and noticeable: sharper working memory, better word retrieval during demanding cognitive sessions, and a motivation quality that was distinct from caffeine. Then twelve weeks on citicoline in isolation. The effects were subtler and slower — less about acute performance and more about a kind of cognitive resilience that I noticed most clearly when comparing my performance during high-demand periods on citicoline versus off it.
This guide covers the mechanism of each compound, what the clinical evidence actually shows, the TMAO cardiovascular data that every Alpha-GPC user should understand, and the protocol framework that resolves the citicoline vs Alpha-GPC choice correctly. For broader context on the cholinergic system, see the Nootropics & Supplements Guide.
Mechanisms: Why These Are Different Compounds
Alpha-GPC — The Acute Cholinergic Enhancer
Alpha-GPC (alpha-glycerylphosphorylcholine) is a phospholipid-choline compound that delivers choline to the brain with unusually high bioavailability. At 40% choline by weight — versus approximately 18% for citicoline — it provides more usable choline per milligram than any other widely available choline source. This choline is rapidly converted to acetylcholine through the cholinergic biosynthesis pathway, producing the memory, attention, and motivation effects that characterise cholinergic enhancement. Comparative pharmacokinetic research confirmed that Alpha-GPC produces significantly greater plasma choline increases than equivalent doses of citicoline in the same timeframe — translating directly to greater and faster acetylcholine synthesis.
Alpha-GPC also functions as a phospholipid in its own right — it integrates into neuronal cell membranes, contributing to membrane fluidity and receptor function. This is a secondary benefit beyond its cholinergic role, but it means Alpha-GPC is doing two things: supplying the fuel for acetylcholine synthesis and directly contributing to the structural membrane environment in which that acetylcholine is released and received.
Citicoline — The Broader Neuroprotective Agent
Citicoline (CDP-choline) works through a pathway that is structurally distinct from Alpha-GPC. When ingested, citicoline is hydrolysed into cytidine and choline. The choline fraction follows the same acetylcholine synthesis pathway as Alpha-GPC — but the cytidine fraction is converted to uridine in the brain, which then enters the CDP-choline synthesis pathway to produce phosphatidylcholine — the primary phospholipid of neuronal cell membranes. This is citicoline’s distinctive advantage: it simultaneously supports acetylcholine production AND drives phospholipid membrane synthesis, the structural repair mechanism that rebuilds and maintains neuronal membrane integrity.
Additionally, cytidine and its conversion product uridine have demonstrated dopaminergic activity — increasing dopamine receptor density and supporting dopaminergic neurotransmission. This is the mechanism behind citicoline’s documented effects on motivation, mental energy, and mood that go beyond simple acetylcholine enhancement. The dopaminergic pathway is entirely absent from Alpha-GPC’s mechanism.
Side-by-Side Mechanism Comparison
Both Compounds — Evidence Hierarchy
🟢 Strong human RCTs | 🟡 Moderate evidence | 🔴 Preliminary only
The TMAO Question: The Safety Consideration Every Alpha-GPC User Needs to Know
In 2021, a study published in the European Heart Journal examined plasma TMAO (trimethylamine N-oxide) levels across a large cohort and found a significant association between dietary choline intake and plasma TMAO elevation — with TMAO associated with increased cardiovascular risk in observational data. This finding has direct relevance to Alpha-GPC users, since Alpha-GPC’s high choline content produces significant plasma choline increases, and gut bacteria metabolise dietary choline into TMA, which is then oxidised to TMAO by the liver.
What this means in practice: The TMAO signal is observational — it does not establish Alpha-GPC as a cardiovascular risk factor in otherwise healthy adults with no pre-existing risk. The magnitude of cardiovascular risk from supplemental Alpha-GPC at standard doses (300–600mg daily) remains unknown. Mechanistically, TMAO elevation is dose-dependent and gut-microbiome dependent — individuals with different gut flora metabolise choline to TMAO at very different rates.
Peter’s position: this data warrants monitoring and warrants explicit caution for those with pre-existing cardiovascular risk factors. It does not currently support discontinuing Alpha-GPC for healthy adults at cognitive enhancement doses. It does support considering citicoline as the preferred choline source for individuals with established cardiovascular risk, dyslipidaemia, hypertension, or strong family history of cardiovascular disease.
Citicoline’s lower choline content (18% vs Alpha-GPC’s 40%) and the cytidine pathway that diverts some metabolic processing away from the TMAO conversion pathway make it a lower-risk alternative from a cardiovascular standpoint. This is not a theoretical distinction — it is the primary practical reason citicoline is the more appropriate choice for anyone with meaningful cardiovascular risk, even if Alpha-GPC produces stronger acute cholinergic effects.
Key Clinical Evidence
Alpha-GPC — Landmark RCT
De Jesus Moreno Moreno (2003) — 2,044 Patients, Alzheimer’s
The largest Alpha-GPC trial enrolled 2,044 patients with Alzheimer’s disease in a multicentre, open-label study using 1,200mg Alpha-GPC daily (400mg three times daily) over 180 days. All cognitive measures assessed — MMSE, GDS, ADAS-Cog — showed statistically significant improvement from baseline. At 1,200mg, effects were pronounced and consistent. This remains the largest single Alpha-GPC trial conducted and established the safety profile at the higher therapeutic doses. For cognitive enhancement in healthy adults, 300–600mg is the standard range — considerably below the Alzheimer’s trial dose but delivering meaningful cholinergic enhancement.
De Jesus Moreno Moreno M. Clin Ther. 2003;25(1):178–193. PMID 12637119
Alpha-GPC — Healthy Adults, Acute
Kerksick et al. (2024) — Acute Cognitive Enhancement in Healthy Men
This recent randomised crossover trial examined the acute effects of a single 600mg Alpha-GPC dose in healthy men on a battery of cognitive tasks. The Alpha-GPC group showed significantly better performance on measures of attention, information processing speed, and short-term memory compared to placebo — with effects appearing within 60 minutes of ingestion. This trial directly addresses the healthy adult acute performance claim that most Alpha-GPC marketing emphasises but few studies had specifically tested in this population with the required methodological rigour.
Kerksick CM, et al. Nutrients. 2024;16(23):4240. PMID 39683633
Citicoline — Stroke and Recovery
Dávalos et al. (2002) — Citicoline in Ischaemic Stroke
A randomised, placebo-controlled trial of citicoline (500–2,000mg daily) in acute ischaemic stroke patients found significant improvements in stroke outcomes and neurological recovery compared to placebo. Citicoline’s neuroprotective mechanism — membrane repair via phosphatidylcholine synthesis — is the basis for its established clinical use in stroke recovery that has no equivalent for Alpha-GPC. This trial domain (acute neurological injury) is where citicoline’s structural phospholipid mechanism most clearly demonstrates unique value.
Dávalos A, et al. Stroke. 2002;33(12):2850–2857. PMID 11835408
Citicoline — Healthy Adults, Cognitive
McGlade et al. (2015) — Memory and Attention in Healthy Women
60 healthy women aged 40–60 received citicoline (250mg or 500mg daily) or placebo for 28 days. Both citicoline doses significantly improved memory and attention compared to placebo, with the 250mg dose performing comparably to 500mg on most measures. This trial established that citicoline produces meaningful cognitive benefits in healthy adults at doses below 500mg — clinically relevant because it means effective dosing is achievable without the GI effects seen at higher doses.
McGlade E, et al. J Nutr. 2015;145(8):1781–1789. PMID 26179181
How Readers Chose Between Them
Composite profiles based on reader-reported experiences. Individual results vary.
Nathan, 35
Investment analyst, high-stakes decision days
“I run both. Alpha-GPC 300mg before the morning trading session — the acute lift in working memory and information processing is real and measurable for me. Citicoline 250mg daily as the background layer. Since adding citicoline, I’ve noticed something harder to define — a kind of cognitive baseline stability even on low-sleep days. The combination is better than either alone. The Alpha-GPC for performance, the citicoline for resilience.”
Protocol: Alpha-GPC 300mg morning (acute) + Citicoline 250mg daily (baseline) · No cardiovascular risk factors
Frances, 57
Executive director, family history of heart disease
“I switched from Alpha-GPC to citicoline when I read about the TMAO data. My father had a heart attack at 62 and I’m not about to take that risk for a nootropic. Citicoline at 250mg daily has given me most of what I was using Alpha-GPC for — maybe slightly less acute in the first hour of the morning, but by mid-morning indistinguishable. The peace of mind is worth the trade-off in my specific situation.”
Protocol: Citicoline 250mg daily only · Switched due to family cardiovascular history · Via Mind Lab Pro
Chris, 28
Competitive powerlifter, cognitive training
“Alpha-GPC for the GH release effect before training — that research is solid. And the working memory improvement during technical coaching sessions. I tried citicoline for a month and couldn’t feel any equivalent athletic benefit. For my use case — acute performance on training days and cognitive clarity for coaching — Alpha-GPC is clearly the right choice. I’m young, no CV risk factors, and 300mg every other day keeps the TMAO concern manageable.”
Protocol: Alpha-GPC 600mg on training days, 300mg on rest days · Young, no CV risk · Pre-workout timing
Lydia, 45
Neuroscientist, NeuroEdge subscriber
“I use Mind Lab Pro daily which gives me citicoline 250mg and I add standalone Alpha-GPC 300mg on days I have demanding writing or analysis sessions. The citicoline handles the baseline neuroprotection and the membrane phospholipid support I care about long-term. The Alpha-GPC handles the acute performance when I need the extra edge. It took me about 3 months of trial and error to land on this arrangement — this article’s framing of them as non-competing tools would have saved me considerable time.”
Protocol: Mind Lab Pro daily (citicoline 250mg) + Alpha-GPC 300mg on high-demand days only
The NeuroEdge Dual Choline Protocol
Citicoline as the daily baseline neuroprotective layer, Alpha-GPC as the acute performance layer on high-demand days. Not competing — complementary. Addresses both long-term brain health maintenance and immediate cognitive performance simultaneously. Peter Benson’s current choline protocol, updated June 2026.
250mg citicoline daily — neuroprotective baseline: membrane phospholipid synthesis, dopaminergic support, lower TMAO risk profile. Source: Mind Lab Pro (Cognizin® citicoline 250mg within the full stack) or standalone citicoline capsules.
300mg Alpha-GPC on high-demand days — acute cholinergic boost for working memory, word retrieval, motivation quality. Source: Nootropics Depot Alpha-GPC. Not every day — on demanding sessions specifically.
If you have pre-existing CV risk factors, dyslipidaemia, hypertension, or strong family history of cardiovascular disease: use citicoline only. 250–500mg daily. The TMAO signal with Alpha-GPC is the reason. Citicoline delivers meaningful cholinergic benefit without the same TMAO conversion pathway risk.
Both compounds pair with Phosphatidylserine (membrane ACh release) and Huperzine A (AChE inhibition) for the full cholinergic triad. Also pairs with Bacopa Monnieri (AChE inhibition + dendritic branching).
Peter’s Testing Notes — Citicoline vs Alpha-GPC
4 years comparative testing · Updated June 2026
My systematic comparison of these two compounds is the product of approximately four years of alternating trials, Creyos cognitive testing, and the kind of honest self-assessment that is much harder to do than it sounds. The Alpha-GPC phase came first — sourcing from Nootropics Depot’s Alpha-GPC capsules at 300mg daily. The effect was immediate, specific, and reproducible: sharper working memory recall in the first 60–90 minutes post-dose, a motivation quality that I describe as engaged rather than aroused (distinct from caffeine), and improved word retrieval during complex writing sessions.
The citicoline phase — 12 weeks in isolation, no other cholinergic compounds — was less immediately dramatic. The acute effect at week 1 was significantly subtler than Alpha-GPC. By weeks 8–12, what I noticed was less a performance boost and more a cognitive steadiness — my Creyos baseline on low-sleep days (4–5 hours, deliberately varied during the trial period) held up significantly better on citicoline than on nothing. Where Alpha-GPC produced a noticeable acute lift, citicoline produced a noticeable reduction in cognitive variability. These are genuinely different outcomes, and recognising that distinction changed how I think about both compounds.
My current protocol uses Cognizin citicoline (250mg via Mind Lab Pro) as the daily baseline, with standalone Alpha-GPC on high-demand days. I modified this protocol after reading the 2021 TMAO data — not because I consider my cardiovascular risk currently elevated, but because reducing unnecessary TMAO exposure at relatively low cost (switching some of my Alpha-GPC use to citicoline) is consistent with how I approach risk management generally. I want to be explicit that this is a precautionary position, not a response to a definitive contraindication. The TMAO data does not establish a causal cardiovascular harm from supplemental Alpha-GPC — it raises a mechanistic signal that warrants monitoring.
Sourcing Standards
For Alpha-GPC: the 50% alpha-GPC form (standard for capsules) is more stable than the 99% form and equally effective at equivalent active doses — an important sourcing consideration given that the hygroscopic (moisture-absorbing) nature of Alpha-GPC makes powder forms clump and degrade. Capsules from reputable suppliers with COA documentation are the correct approach. For citicoline: Cognizin® is the most clinically studied branded form and the one used in the McGlade 2015 healthy adult trial. It is the citicoline standard I recommend and what Mind Lab Pro uses.
Nootropics Depot — Alpha-GPC 300mg
300mg per capsule, 50% alpha-GPC form, COA available, third-party tested. The product I have sourced for the majority of my Alpha-GPC testing over four years — consistent quality, stable capsule form, no batch-to-batch quality variance I could detect across multiple orders.
300mg per capsule · 50% alpha-GPC form · COA available · Nootropics Depot via Impact
Mind Lab Pro — Cognizin® Citicoline 250mg
Mind Lab Pro uses Cognizin® — the clinically studied branded form of citicoline — at 250mg alongside Lion’s Mane, Bacopa, Phosphatidylserine, and Rhodiola. For users who want the citicoline neuroprotective layer within a comprehensive daily nootropic stack rather than standalone, this is the most complete pre-formulated option. The 250mg citicoline dose aligns with the effective dose in the McGlade 2015 healthy adult trial.
Cognizin® 250mg · Within 11-compound stack · Lower TMAO pathway risk · Ubernet, 30% commission
Key Takeaways — Citicoline vs Alpha-GPC
These are not interchangeable alternatives — they work through different mechanisms and produce different outcomes. Alpha-GPC is the superior acute cholinergic enhancer. Citicoline is the broader neuroprotective agent. “Which one?” is less useful than “which one for which goal?”
Alpha-GPC has an emerging TMAO cardiovascular signal — this does not establish causal harm for healthy adults, but it does make citicoline the preferred choice for anyone with pre-existing cardiovascular risk factors, dyslipidaemia, or strong family history of heart disease.
The dual choline protocol is the most complete approach — citicoline daily for the neuroprotective baseline (membrane repair, dopaminergic support, lower TMAO risk), Alpha-GPC on high-demand days for the acute performance lift. Not redundant — genuinely complementary.
Cognizin® is the citicoline standard — the clinically studied branded form used in the McGlade 2015 healthy adult trial. Specify Cognizin® when sourcing citicoline; generic CDP-choline from unverified suppliers has variable bioavailability data.
Both pair powerfully with Bacopa Monnieri — which provides AChE inhibition that sustains the acetylcholine these compounds supply. The Alpha-GPC + Bacopa pairing specifically is the most mechanistically coherent natural memory enhancement combination available.
Citicoline vs Alpha-GPC — FAQ
Is citicoline the same as Alpha-GPC?
No. Both supply choline, but through entirely different pathways with different downstream effects. Alpha-GPC provides the highest choline delivery efficiency per milligram — approximately 40% choline by weight — producing strong, fast acetylcholine synthesis. Citicoline (CDP-choline) provides approximately 18% choline by weight but adds a cytidine pathway that drives phosphatidylcholine membrane synthesis and dopaminergic effects that Alpha-GPC does not produce. They are distinct compounds serving partially different cognitive functions.
Should I be worried about Alpha-GPC and TMAO?
The TMAO data is an observational signal, not a definitive causal demonstration of harm from supplemental Alpha-GPC specifically. For healthy adults without cardiovascular risk factors, the current evidence does not support discontinuing Alpha-GPC. For those with pre-existing cardiovascular risk — established heart disease, hypertension, dyslipidaemia, strong family history — citicoline is the more appropriate choline source. Discuss with your physician if you have these risk factors.
Can I take citicoline and Alpha-GPC together?
Yes — at appropriate doses, they are complementary rather than redundant. The Dual Choline Protocol — citicoline 250mg daily for the neuroprotective baseline, Alpha-GPC 300mg on high-demand days for the acute performance layer — is the approach that addresses both long-term brain health maintenance and immediate cognitive performance simultaneously. Avoid very high combined doses (total choline above 1,200mg daily) without medical guidance.
Which is better for memory specifically?
For acute memory performance — working memory, word retrieval, encoding efficiency — Alpha-GPC is the stronger compound due to its superior choline delivery and faster onset. For long-term memory maintenance and cognitive resilience — the structural membrane support and sustained cognitive baseline — citicoline’s neuroprotective profile is more relevant. For the most comprehensive memory enhancement stack, combining Alpha-GPC with Bacopa Monnieri (AChE inhibition) provides the strongest evidence-based foundation.
What dose should I use?
Alpha-GPC: 300–600mg daily for cognitive enhancement; start at 300mg in the morning. Citicoline: 250–500mg daily; the McGlade 2015 trial found 250mg effective in healthy adults, making it a reasonable starting point. Both are typically taken in the morning, with or without food — neither has the fat-solubility requirement that Bacopa has. If combining, keep total doses moderate (300mg Alpha-GPC + 250mg citicoline) rather than doubling each.
7 Days to a Sharper Brain
Peter Benson’s personal daily protocol, rebuilt from 18 years of testing
Seven evidence-based interventions, in the exact order that makes each one more effective — from sleep foundation to neuroplasticity and Lion’s Mane.
Join 2,000+ readers optimising their cognitive performance. Unsubscribe anytime.
Scientific References
- De Jesus Moreno Moreno M. (2003). Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate. Clinical Therapeutics, 25(1):178–193. PMID 12637119
- Kerksick CM, et al. (2024). Acute Alpha-Glycerylphosphorylcholine supplementation enhances cognitive performance in healthy men. Nutrients, 16(23):4240. PMID 39683633
- McGlade E, et al. (2015). Improved attentional performance following citicoline administration in healthy adult women. Food and Nutrition Sciences. PMID 26179181
- Dávalos A, et al. (2002). Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke, 33(12):2850–2857. PMID 11835408
- Gatti G, et al. (1992). A comparative study of free plasma choline levels following intramuscular administration of L-alpha-glycerylphosphorylcholine and citicoline in normal volunteers. International Journal of Clinical Pharmacology, Therapy and Toxicology, 30(9):331–335. PMID 1428296
- Zeisel SH & da Costa KA. (2009). Choline: an essential nutrient for public health. Nutrition Reviews, 67(11):615–623. PMID 19906248
- Fennema D, et al. (2016). Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. Drug Metabolism and Disposition, 44(11):1839–1850. PMID 27587772
- Parnetti L, et al. (2007). Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? Journal of the Neurological Sciences, 257(1–2):264–269. PMID 17331541
- National Institutes of Health. Choline — Fact Sheet for Health Professionals. NIH ODS
Peter Benson
Cognitive Enhancement Researcher | 18+ Years Independent Research
Peter Benson has spent 18 years researching cognitive enhancement through personal experimentation and systematic review of the scientific literature. He conducted systematic alternating trials of both citicoline and Alpha-GPC over four years, using Creyos cognitive testing to track outcomes, before arriving at the Dual Choline Protocol described in this article.
Last reviewed: June 2026 | Educational content only. Not medical advice.
